Back to News
Market Impact: 0.22

Cocrystal Pharma Announces Last Subject Dosed In Phase 1b Norovirus Study

Source: Nasdaq

Healthcare & Biotech

Cocrystal Pharma (COCP) announced that it dosed the final participant in its Phase 1b human challenge study of CDI-988 for norovirus prevention and treatment. Completion of dosing is a positive clinical-development milestone, but no efficacy, safety, or financial results were disclosed.

AllMind Terminal

AI-powered research, real-time alerts, and portfolio analytics for institutional investors.

Request Trial

Market Sentiment

Overall Sentiment

mildly positive

Sentiment Score

0.25

Ticker Sentiment

COCP0.45

More News